Remdesivir is an antiviral nucleotide analogue used for therapy of severe novel coronavirus disease 2019
(COVID-19) caused by severe acute respiratory syndrome (SARS) coronavirus 2 (CoV-2) infection.
Remdesivir therapy is given intravenously for 3 to 10 days and is frequently accompanied by transient,
reversible mild-to-moderate elevations in serum aminotransferase levels but has been only rarely linked to
instances of clinically apparent liver injury, its hepatic effects being overshadowed by the systemic effects of
COVID-19

READ MORE